Company intelligence / Profile preview

ImmuCell

Portland, Maine, United Statesimmucell.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

ImmuCell’s First Defense® products are commercially available and provide immediate passive immunity to newborn calves against E. coli, coronavirus, and rotavirus using colostrum-derived antibodies[2][5]. The company’s lead pipeline candidate Re-Tain®, a purified nisin intramammary treatment for subclinical mastitis in dairy cows as an alternative to antibiotics, has completed major facility expansion and submitted its final technical sections to the FDA. As of June 2025 it remains under regulatory review with investigational use initiated but not yet fully approved[6][9].

Therapeutic areas: Infectious Diseases
Modalities: Live biotherapeutic product therapyProtein (colostrum-derived antibodies)Peptide (nisin)
Industry: Veterinary

Drug pipeline

2 assets

First Defense

Commercial

Indications: Calf scours, Bovine enteritis

1 more asset in the full pipeline.

Partnerships

Contract manufacturing partners for drug substance/product facilities[9]; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on ImmuCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuCell.